0001628280-26-025811
SEC filingMobia Medical is a commercial-stage medical device company with its first and only FDA-approved solution for chronic ischemic stroke survivors with moderate-to-severe upper extremity impairment, having experienced rapid revenue growth since full commercial launch in 2023; this S-1 offering is critical to fund continued commercial expansion, clinical evidence generation, and market access efforts amid ongoing losses and going concern uncertainty.
Mobia Medical operates at the intersection of neurostimulation and post-stroke rehabilitation, targeting a large, underserved population of chronic ischemic stroke survivors with upper extremity impairments — estimated at over 4 million in the U.S. alone. Its proprietary Vivistim Paired VNS System leverages vagus nerve stimulation synchronized with task-specific physical therapy to drive neuroplasticity, and is supported by robust clinical evidence, including a pivotal triple-blind, sham-controlled trial demonstrating two- to three-times greater functional improvement versus intensive rehabilitation alone. The company’s business model centers on a highly concentrated customer base: ~1,500 primary and comprehensive stroke centers in the U.S., which are surrounded by networks of therapy sites — enabling efficient commercial deployment through Territory Managers and Therapy Development Specialists. Revenue reflects strong execution against this model: $32.0 million in 2025, up 104.8% year-over-year, with gross margin improving to 81.1%, indicating pricing discipline and scalable unit economics. However, financial performance remains pre-profitability — net loss widened to $46.5 million in 2025, and the company reported negative operating cash flow, an accumulated deficit of $157.8 million, and concluded that its history of losses raises substantial doubt about its ability to continue as a going concern. This underscores the strategic importance of the offering: proceeds will fund commercial expansion, R&D, and working capital, with no debt repayment or acquisition obligations disclosed. The offering terms reflect typical IPO mechanics — shares to be listed on NASDAQ under ticker MOBI, with underwriters holding a 30-day greenshoe option. Key risks are both structural and operational: lack of broad insurance coverage (most commercial payors deem Vivistim experimental), dependence on just two qualified suppliers for mission-critical components (Integer for the implantable pulse generator, Cirtec for the lead), and the finite five-year battery life of the IPG, which necessitates future explants and introduces long-term adoption friction. Governance and management reinforce credibility: seasoned executives with deep MedTech commercialization experience, including former leaders from Abbott, AtriCure, and SentreHEART, alongside a board composed of directors from Pulmonx, Inspire Medical, and Cooper Companies. The company’s competitive position is anchored in its FDA PMA approval, breakthrough device designation, and exclusive license to foundational UT Dallas patents — though those rights are partially co-owned and subject to government march-in provisions. While the market opportunity is compelling — $30+ billion initial opportunity based on average selling price — its realization hinges on expanding payer coverage, scaling a specialized field team, and sustaining durable clinical outcomes beyond one-year follow-up. Given the size of the offering, the company’s stage, and the magnitude of its funding gap, this S-1 represents a high-materiality inflection point for investors assessing viability of a novel therapeutic pathway in chronic neurorehabilitation.